



ASX & Media Release

## Collaborations to Support Advancement of Anti-Cancer Product PAT-SM6

- Patrys collaborates with research organisations to supplement PAT-SM6 development program
- Extension of PAT-SM6 preclinical data to contribute to clinical trial design and conduct

**Melbourne, Australia; 20 June, 2011:** Patrys Limited (ASX: PAB; Company), a clinical stage biopharmaceutical company focused on the development of novel treatments for cancer, has today announced multiple preclinical collaborations to support the development program of lead anti-cancer compound PAT-SM6.

PAT-SM6 is currently in a Phase 1 clinical trial for melanoma at Royal Adelaide Hospital. Patrys is extending its preclinical program to generate additional data and evidence to supplement the ongoing clinical program. This new program will also allow Patrys to work more closely with key specialist contract research organisations, an important element towards the successful commercialisation of PAT-SM6.

Preclinical work on Patrys' R&D pipeline of natural human antibody therapeutics has to date largely been conducted in-house at the Company's research facility in Würzburg, Germany. In order to expand and accelerate the Company's commercialisation program, Patrys has signed collaborations with Clarity Pharmaceuticals Pty Ltd and vivoPharm Pty Ltd.

"Undertaking further preclinical work on a drug compound in parallel with a clinical program can lead to superior outcomes, particularly when the compound has multiple disease targets," said Patrys' Dr Marie Roskrow.

"The establishment and continuation of these relationships reflects both the collaborative approach to our R&D and the clinical focus of the programs. In addition, the preclinical studies will add to the body of evidence moulding the PAT-SM6 development pathway."

Clarity Pharmaceuticals is a company with intellectual property specific to radio-labelling biologics including antibodies for imaging purposes. Clarity has access to a vast network of resources and specialist equipment located at the University of Queensland, the University of Melbourne and the Australian Nuclear and Science Technology Organisation. Patrys will undertake imaging studies with its clinical candidate PAT-SM6 to better understand both localisation and distribution, which will assist in the design of future clinical programs.

The second collaboration is with vivoPharm, a highly respected contract research organisation specialising in both *in vitro* and *in vivo* preclinical concept validation. vivoPharm has many years of experience using human xenograft tumour models and offers a range of more than 60 fully characterised cell lines that can be used for various tumour models, in addition to providing preclinical toxicology capabilities. Patrys has already initiated a number of studies at vivoPharm to support the PAT-SM6 clinical program.

Patrys Vice President, Research and Development, Dr. Frank Hensel added: "Tapping into specialist expertise to assist in answering fundamental questions about PAT-SM6 is essential for the accelerated progress of our clinical program and extends our preclinical package."

**-Ends-**

**For further information, please contact:**

***Patrys Limited:***

Dr. Deanne Greenwood  
Director, Business Development  
P: +61 3 9670 3273

[info@patrys.com](mailto:info@patrys.com)

***Patrys IR:***

Rebecca Wilson  
Buchan Consulting  
P: 0417 382 391

[rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

***Patrys Media:***

Tom Donovan  
Buchan Consulting  
P: +61 3 9866 4722

[tdonovan@bcg.com.au](mailto:tdonovan@bcg.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at [www.patrys.com](http://www.patrys.com).

**About PAT-SM6:**

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to melanoma, PAT-SM6 has shown particularly strong promise. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action. In October 2010, Patrys initiated a human clinical trial to evaluate PAT-SM6 as a therapy for melanoma. To date, the first group of patients has been treated and Patrys received approval to progress the clinical trial. The clinical trial is taking place at the Royal Adelaide Hospital (RAH) Cancer Centre and associated Pain and Anaesthesia Research Clinic.

**About Clarity Pharmaceuticals:**

Based in Sydney, Australia, Clarity is focused on PET imaging of biological molecules and offers novel chelators and imaging services to external parties. Clarity has access to world-class infrastructure and researchers in the field of nuclear medicine. Clarity's niche is the field of theranostics and companion diagnostics. Clarity's internal research programs are focused on oncology, paediatrics, neurology and cardiovascular disease. More information can be found at [www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com).

**About vivoPharm:**

vivoPharm is a contract research organisation (CRO) based in Adelaide, South Australia. It offers integrated preclinical services - including *in vitro* and *in vivo* efficacy, safety, toxicology (GLP), pharmacodynamic and pharmacokinetic analyses - to the biotechnology and pharmaceutical industries. The company's advanced animal facilities, laboratories and corporate headquarters are located in Adelaide, Australia. It also has a European office based in Munich, Germany. vivoPharm will open its American laboratory facility in Hershey, Pennsylvania in September 2011. vivoPharm's operations are GLP compliant and meet the highest industrial standards, acknowledged by customers worldwide.